Literature DB >> 9707621

Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells.

P B Robbins1, D C Skelton, X J Yu, S Halene, E H Leonard, D B Kohn.   

Abstract

Retroviral vectors based on the Moloney murine leukemia virus (MoMuLV) have shown inconsistent levels and duration of expression as well as a propensity for the acquisition of de novo methylation in vivo. MoMuLV-based vectors are known to contain sequences that are capable of suppressing or preventing expression from the long terminal repeat. Previously, we constructed a series of modified retroviral vectors and showed that they function significantly better than MoMuLV-based vectors in vitro. To test the efficacy of the modified vectors in hematopoietic stem cells in vivo, we examined gene expression and proviral methylation in differentiated hematopoietic colonies formed in the spleens of mice after serial transplantation with transduced bone marrow (2 degreesCFU-S). We found a significant increase in the frequency of expression with our modified vectors (>90% expression in vector DNA containing 2 degreesCFU-S) over the frequency observed with the standard MoMuLV-based vector (28% expression in vector containing 2 degreesCFU-S). Expression from the modified vectors was highly consistent, with expression in >50% of the vector-containing 2 degreesCFU-S from all 20 transplant recipients analyzed, whereas expression from the standard MoMuLV-based vector was inconsistent, with expression in 0-10% of the vector containing 2 degreesCFU-S from 8 recipients and expression in >50% of the vector-containing 2 degreesCFU-S from 4 other recipients. In addition, we established that the modified vectors had a lower level of DNA methylation than the control vector. These findings represent significant advances in the development and evaluation of effective retroviral vectors for application in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707621      PMCID: PMC21482          DOI: 10.1073/pnas.95.17.10182

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Authors:  J E TILL; E A McCULLOCH
Journal:  Radiat Res       Date:  1961-02       Impact factor: 2.841

2.  Sustained high-level reconstitution of the hematopoietic system by preselected hematopoietic cells expressing a transduced cell-surface antigen.

Authors:  R Pawliuk; C J Eaves; R K Humphries
Journal:  Hum Gene Ther       Date:  1997-09-01       Impact factor: 5.695

3.  Expression levels by retroviral vectors based upon the N2 and the MFG backbones.

Authors:  W Krall; D B Kohn
Journal:  Gene Ther       Date:  1996-04       Impact factor: 5.250

4.  Host cis-mediated extinction of a retrovirus permissive for expression in embryonal stem cells during differentiation.

Authors:  C Laker; J Meyer; A Schopen; J Friel; C Heberlein; W Ostertag; C Stocking
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy.

Authors:  J Byun; S H Kim; J M Kim; S S Yu; P D Robbins; J Yim; S Kim
Journal:  Gene Ther       Date:  1996-09       Impact factor: 5.250

6.  Negative regulation of viral enhancers in undifferentiated embryonic stem cells.

Authors:  C M Gorman; P W Rigby; D P Lane
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

Review 7.  The current status of gene therapy using hematopoietic stem cells.

Authors:  D B Kohn
Journal:  Curr Opin Pediatr       Date:  1995-02       Impact factor: 2.856

8.  Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.

Authors:  T D Palmer; G J Rosman; W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

9.  Deletions in a recombinant retrovirus genome associated with its expression in embryonal carcinoma cells.

Authors:  M Taketo; D J Shaffer
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

10.  Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus.

Authors:  J R Flanagan; K G Becker; D L Ennist; S L Gleason; P H Driggers; B Z Levi; E Appella; K Ozato
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

View more
  27 in total

1.  Retroviral expression in embryonic stem cells and hematopoietic stem cells.

Authors:  S R Cherry; D Biniszkiewicz; L van Parijs; D Baltimore; R Jaenisch
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

2.  Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy.

Authors:  Jana Blazkova; Danielle Murray; J Shawn Justement; Emily K Funk; Amy K Nelson; Susan Moir; Tae-Wook Chun; Anthony S Fauci
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

3.  Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report.

Authors:  Barbara C Engel; Greg M Podsakoff; Joanna L Ireland; E Monika Smogorzewska; Denise A Carbonaro; Kathy Wilson; Ami Shah; Neena Kapoor; Mirna Sweeney; Mark Borchert; Gay M Crooks; Kenneth I Weinberg; Robertson Parkman; Howard M Rosenblatt; Shi-Qi Wu; Michael S Hershfield; Fabio Candotti; Donald B Kohn
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

Review 4.  In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus.

Authors:  Leonard Chávez; Steven Kauder; Eric Verdin
Journal:  Methods       Date:  2010-06-02       Impact factor: 3.608

5.  Human beta interferon scaffold attachment region inhibits de novo methylation and confers long-term, copy number-dependent expression to a retroviral vector.

Authors:  Q Dang; J Auten; I Plavec
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Dynamic analysis of proviral induction and De Novo methylation: implications for a histone deacetylase-independent, methylation density-dependent mechanism of transcriptional repression.

Authors:  M C Lorincz; D Schübeler; S C Goeke; M Walters; M Groudine; D I Martin
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

7.  Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.

Authors:  Fabio Candotti; Kit L Shaw; Linda Muul; Denise Carbonaro; Robert Sokolic; Christopher Choi; Shepherd H Schurman; Elizabeth Garabedian; Chimene Kesserwan; G Jayashree Jagadeesh; Pei-Yu Fu; Eric Gschweng; Aaron Cooper; John F Tisdale; Kenneth I Weinberg; Gay M Crooks; Neena Kapoor; Ami Shah; Hisham Abdel-Azim; Xiao-Jin Yu; Monika Smogorzewska; Alan S Wayne; Howard M Rosenblatt; Carla M Davis; Celine Hanson; Radha G Rishi; Xiaoyan Wang; David Gjertson; Otto O Yang; Arumugam Balamurugan; Gerhard Bauer; Joanna A Ireland; Barbara C Engel; Gregory M Podsakoff; Michael S Hershfield; R Michael Blaese; Robertson Parkman; Donald B Kohn
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

8.  CpG methylation controls reactivation of HIV from latency.

Authors:  Jana Blazkova; Katerina Trejbalova; Françoise Gondois-Rey; Philippe Halfon; Patrick Philibert; Allan Guiguen; Eric Verdin; Daniel Olive; Carine Van Lint; Jiri Hejnar; Ivan Hirsch
Journal:  PLoS Pathog       Date:  2009-08-21       Impact factor: 6.823

9.  Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation.

Authors:  M A Sadat; S Dirscherl; L Sastry; J Dantzer; N Pech; S Griffin; T Hawkins; Y Zhao; C N Barese; S Cross; A Orazi; C An; W S Goebel; M C Yoder; X Li; M Grez; K Cornetta; S D Mooney; M C Dinauer
Journal:  Gene Ther       Date:  2009-12       Impact factor: 5.250

10.  Serial bone marrow transplantation reveals in vivo expression of the pCLPG retroviral vector.

Authors:  Paula Fratini; Bryan E Strauss
Journal:  Virol J       Date:  2010-01-22       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.